چكيده لاتين :
Introduction- The anticoagulation activity of warfarin is monitored by the prothrombin time (PT)
using the international normalization ratio (INR). Factors such as genetic polymorphism and
ethnic differences can cause an unpredictable dose response. In our study, the primary end
point was time in days to therapeutic INR in the Iranian race. The secondary end point was
time in days to stable dose for our patients, and the third end point was determination of stable
dose related to sex and age distribution of our patients.
Method- The anticoagulation clinic records of patients taking warfarin during an index period were
retrospectively reviewed. INR measurements were performed on citrated venous blood
samples. Under-anticoagulation was defmed as any out of range INR95% by day 35. The mean stable dose showed an inverse relation with
the day 5 INR. However, about 12% of the patients required a fmal stable dose of (LESS THAN) 2.5 mg.
No patients suffered any hemorrhagic or thrombosis episodes during the fIrst month of
warfarin therapy. After the first month, hemorrhagic complications such as gum bleeding,
hematuria, and bloody stool were seen in about 5.5%; however, hospitalization due to
hemorrhagic cardiovascular accident was less than 0.7% and thrombosis events were less than
2%. We conclude that warfarin dose during the second and third weeks was highly predictive
of the patientsי "stable dose", which is different from the time to reach the therapeutic INR
level
